A planned $425m merger between a Cheshire drug developer and a US counterpart has been called off.
The deal was first announced last month when the boards of Alderley Park-based Redx Pharma and Jounce Therapeutics both unanimously recommended the deal to their shareholders.
However, the deal came under threat earlier this month when Jounce became the target of an "unsolicited" takeover bid from one of its rivals.
